Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer.

OBJECTIVE The objective of our study was to determine the relative accuracy of mammography, sonography, and MRI in predicting residual tumor after neoadjuvant chemotherapy for breast cancer as compared with the gold standards of physical examination and pathology. SUBJECTS AND METHODS Forty-one women with stage IIB-III palpable breast cancer were prospectively enrolled in a study investigating the effects of sequential single-agent chemotherapy (doxorubicin followed by paclitaxel or vice versa) on tumor imaging. The study cohort consisted of the first 31 patients (age range, 31-65 years; mean, 45 years) who completed the protocol. All underwent physical examination, mammography, sonography, and MRI before and after receiving each neoadjuvant chemotherapeutic drug. Imaging studies were reviewed by two radiologists using conventional lexicons for lesion analysis, and the findings were compared with clinical response and pathology results. RESULTS Complete, partial, and stable clinical response as defined by clinical examination was seen in 15, 14, and two of the 31 patients, respectively. Agreement rates about the degree of response were 32%, 48%, and 55%, respectively, for mammography, sonography, and MRI compared with clinical evaluation and did not differ statistically. Agreement about the rate of response as measured by clinical examination, mammography, sonography, and MRI compared with the gold standard (pathology) was 19%, 26%, 35%, and 71%, respectively. Of the four, MRI agreed with the gold standard significantly more often (p < 0.002 for all three paired comparisons with MRI). When there was disagreement with the gold standard, none of the four exhibited a significant tendency to either under- or overestimate. CONCLUSION MRI appears to provide the best correlation with pathology-better than physical examination, mammography, and sonography-in patients undergoing neoadjuvant chemotherapy. However, MRI may overestimate (6%) or underestimate (23%) residual disease in approximately 29% of the patients (95% confidence interval, 14-48%).

[1]  S. Heywang-Köbrunner,et al.  In situ and minimally invasive breast cancer: morphologic and kinetic features on contrast-enhanced MR imaging , 2000, Magma: Magnetic Resonance Materials in Physics, Biology, and Medicine.

[2]  D. Yeung,et al.  Magnetic resonance imaging of breast lesions—a pathologic correlation , 2007, Breast Cancer Research and Treatment.

[3]  Francesco Sardanelli,et al.  Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? , 2007, European Radiology.

[4]  Jai Hak Lee,et al.  The Clinical Significance of Preoperative MRI for Determination of Surgery in Breast Cancer , 2006 .

[5]  S. Singletary,et al.  Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy , 2006, Annals of Surgical Oncology.

[6]  S. Loibl,et al.  Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial , 2006, Annals of Surgical Oncology.

[7]  Nola Hylton,et al.  MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. , 2006, Magnetic resonance imaging clinics of North America.

[8]  J. Ibarra,et al.  Neoadjuvant Chemotherapy: Mammographic–Pathologic Correlation , 2005 .

[9]  Simak Ali,et al.  Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. , 2005, The Lancet. Oncology.

[10]  G. Minckwitz.  Neoadjuvante Chemotherapie von Mammakarzinomen , 2005, Der Gynäkologe.

[11]  G. Cocconi,et al.  Problems in evaluating response of primary breast cancer to systemic therapy , 2005, Breast Cancer Research and Treatment.

[12]  L. Liberman,et al.  Ductal enhancement on MR imaging of the breast. , 2003, AJR. American journal of roentgenology.

[13]  Elkan F Halpern,et al.  Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. , 2003, Radiology.

[14]  D. Kopans,et al.  Invasive Lobular Carcinoma: Spectrum of Enhancement and Morphology on Magnetic Resonance Imaging , 2003, The breast journal.

[15]  W. Kaiser,et al.  High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. , 2003, The British journal of radiology.

[16]  J. Peterse,et al.  Breast MR imaging in women at increased lifetime risk of breast cancer: clinical system for computerized assessment of breast lesions initial results. , 2002, Radiology.

[17]  R. Warren,et al.  Is breast MRI ever useful in a mammographic screening programme? , 2002, Clinical radiology.

[18]  Ying Lu,et al.  Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. , 2002, AJR. American journal of roentgenology.

[19]  Kuhl Ck.  High-risk screening: multi-modality surveillance of women at high risk for breast cancer (proven or suspected carriers of a breast cancer susceptibility gene). , 2002 .

[20]  S. Jeffrey,et al.  MR imaging features of infiltrating lobular carcinoma of the breast: histopathologic correlation. , 2002, AJR. American journal of roentgenology.

[21]  M. Appetecchia,et al.  A long-standing cystic lymph-node metastasis from occult thyroid carcinoma. , 2002, Journal of experimental & clinical cancer research : CR.

[22]  D B Plewes,et al.  Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  W. Kaiser,et al.  Development, standardization, and testing of a lexicon for reporting contrast‐enhanced breast magnetic resonance imaging studies , 2001, Journal of magnetic resonance imaging : JMRI.

[24]  B. Daniel,et al.  Potential role of magnetic resonance imaging and other modalities in ductal carcinoma in situ detection. , 2001, Magnetic resonance imaging clinics of North America.

[25]  D. Kopans.  Clip placement during sonographically guided breast biopsy. , 2001, AJR. American journal of roentgenology.

[26]  S. Weinstein,et al.  MR imaging of the breast in patients with invasive lobular carcinoma. , 2001, AJR. American journal of roentgenology.

[27]  Ying Lu,et al.  MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer , 2001, Annals of Surgical Oncology.

[28]  E A Sickles,et al.  Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. , 2000, AJR. American journal of roentgenology.

[29]  D Krebs,et al.  Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. , 2000, Radiology.

[30]  T. Pope,et al.  Sonographically guided clip placement facilitates localization of breast cancer after neoadjuvant chemotherapy. , 2000, AJR. American journal of roentgenology.

[31]  D M Ikeda,et al.  Lesion Diagnosis Working Group Report , 1999, Journal of magnetic resonance imaging : JMRI.

[32]  N. Dash,et al.  Usefulness of tissue marker clips in patients undergoing neoadjuvant chemotherapy for breast cancer. , 1999, AJR. American journal of roentgenology.

[33]  C. Kuhl,et al.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? , 1999, Radiology.

[34]  S G Orel,et al.  Differentiating benign from malignant enhancing lesions identified at MR imaging of the breast: are time-signal intensity curves an accurate predictor? , 1999, Radiology.

[35]  M. Christian,et al.  Measuring response in solid tumors: unidimensional versus bidimensional measurement. , 1999, Journal of the National Cancer Institute.

[36]  R. Weisskoff,et al.  CT-guided preoperative needle localization of MR imaging-detected mammographically occult lesions. , 1999, AJR. American journal of roentgenology.

[37]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D B Kopans,et al.  Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. , 1997, Radiology.

[39]  M. Reiser,et al.  Morphologie und Anreicherungsverhalten des duktalen In-situ-Karzinoms in der dynamischen MR-Mammographie bei 1,0 T , 1997 .

[40]  M. Schnall,et al.  MR imaging of ductal carcinoma in situ. , 1997, Radiology.

[41]  W. P. Evans,et al.  Three-dimensional RODEO breast MR imaging of lesions containing ductal carcinoma in situ. , 1996, Radiology.

[42]  G. Bonadonna,et al.  Primary chemotherapy in operable breast cancer. , 1996, Seminars in oncology.

[43]  S E Harms,et al.  Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging , 1996, Cancer.

[44]  D B Kopans,et al.  Benign and malignant breast lesions: differentiation with echo-planar MR imaging. , 1995, Radiology.

[45]  L J van Erning,et al.  MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. , 1994, Radiology.

[46]  G. Calais,et al.  Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm , 1994, Cancer.

[47]  R. Gilles,et al.  Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. , 1994, Radiology.

[48]  M D Schnall,et al.  Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. , 1994, Radiology.

[49]  R. Gilles,et al.  Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. , 1993, Radiology.

[50]  B Asselain,et al.  Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. , 1993, Radiology.

[51]  S E Harms,et al.  MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. , 1993, Radiology.

[52]  G. Calais,et al.  Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers. , 1993, International journal of radiation oncology, biology, physics.

[53]  J. Allison,et al.  Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. , 1993, Magnetic resonance imaging.

[54]  G. Hortobagyi,et al.  Feasibility of breast‐conservation surgery after induction chemotherapy for locally advanced breast carcinoma , 1992, Cancer.

[55]  G. Hortobagyi,et al.  Treatment of locally advanced breast cancer. , 1992, Seminars in oncology.

[56]  I. Gribbestad,et al.  Contrast-enhanced magnetic resonance imaging of the breast. , 1992, Acta oncologica.

[57]  S E Harms,et al.  Three-dimensional gadolinium-enhanced MR imaging of the breast: pulse sequence with fat suppression and magnetization transfer contrast. Work in progress. , 1991, Radiology.

[58]  J H Simon,et al.  Gadopentetate dimeglumine-enhanced chemical-shift MR imaging of the breast. , 1991, AJR. American journal of roentgenology.

[59]  A. Luini,et al.  Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. , 1990, Journal of the National Cancer Institute.

[60]  J T Ennis,et al.  Breast disease: tissue characterization with Gd-DTPA enhancement profiles. , 1990, Radiology.

[61]  S. Heywang,et al.  MR imaging of the breast with Gd-DTPA: use and limitations. , 1989, Radiology.

[62]  W. Kaiser,et al.  MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. , 1989, Radiology.

[63]  G. Hortobagyi,et al.  Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy , 1988, Cancer.

[64]  G. Hortobagyi,et al.  Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. , 1988, Radiology.

[65]  S. Heywang,et al.  [Dynamic contrast medium studies with flash sequences in nuclear magnetic resonance tomography of the breast]. , 1988, Digitale Bilddiagnostik.

[66]  S. Steinberg,et al.  Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. , 1987, Cancer research.

[67]  S. Heywang,et al.  MR imaging of the breast using gadolinium-DTPA. , 1986, Journal of computer assisted tomography.

[68]  D Revel,et al.  Gd-DTPA contrast enhancement and tissue differentiation in MR imaging of experimental breast carcinoma. , 1986, Radiology.

[69]  J. Aisner,et al.  Mastectomy as an adjuvant to chemotherapy for locally advanced or metastatic breast cancer. , 1982, Archives of surgery.

[70]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[71]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[72]  Myer Goldman,et al.  College of radiology , 1969 .